

175409

MEJ

STIC-Biotech/ChemLib

From: Akhavan, Ramin
Sent: Friday, December 30, 2005 12:19 PM
To: STIC-Biotech/ChemLib
Subject: 10/688,299

Contacts: STIC-Biotech/ChemLib

Please conduct a standard search of the following:

1. SID 19

2. SID 51

2C70

Ray Akhavan
Patent Examiner, AU 1636
Remsen Building, 2C84
571-272-0766
ramin.akhavan@uspto.gov

RECEIVED
JAN - 3 2006
TECH/CHEM. DIVISION
(STIC)

Searcher: _____
Searcher Phone: _____
Date Searcher Picked up: _____
Date completed: _____
Searcher Prep Time: _____
Online Time: _____

Type of Search
NA# _____ AA# _____
S/L: _____ Oligomer: _____
Encode/Transl: _____
Structure #: _____ Text: _____
Inventor: _____ Litigation: _____

Vendors and cost where applicable
STN: _____
DIALOG: _____
QUESTEL/ORBIT: _____
LEXIS/NEXIS: _____
SEQUENCE SYSTEM: _____
WWW/Internet: _____
Other (Specify): _____

GenCore version 5.1.6
Copyright (c) 1993 - 2006 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: January 6, 2006, 14:34:06 ; Search time 134 Seconds

(without alignments)
65.579 Million cell updates/sec

Title: US-10-688-299-19

Perfect score: 95
Sequence: 1 MYRQMLSCIALSLALVTNS 20

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 2443163 seqs, 439378781 residues

Total number of hits satisfying chosen parameters: 2443163

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%

Listing first 45 summaries

Database :

A_Geneseq_21:*
1: geneseqp1980s:*
2: geneseqp1990s:*
3: geneseqp2000s:*
4: geneseqp2001s:*
5: geneseqp2002s:*
6: geneseqp2003s:*
7: geneseqp2003bs:*
8: geneseqp2004s:*
9: geneseqp2005s:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	95	100.0	20	1 AAP60901	AAP60901 Sequence
2	95	100.0	20	2 AAR27274	AAR27274 IL2 Signa
3	95	100.0	20	3 AAY43834	AAY43834 Secretary
4	95	100.0	20	4 AAY88092	AAY88092 IL-2 secr
5	95	100.0	20	5 AAB35082	AAB35082 IL-2 secr
6	95	100.0	20	6 AAB45952	AAB45952 Transdomi
7	95	100.0	20	7 AAB399149	AAB399149 IL-2 secr
8	95	100.0	20	8 AAU76401	AAU76401 Interleuk
9	95	100.0	20	9 AAB28695	AAB28695 Interleuk
10	95	100.0	20	5 AAB32975	AAB32975 Interleuk
11	95	100.0	20	6 AAB38473	AAB38473 Signal pe
12	95	100.0	20	6 AAB64910	AAB64910 Interleuk
13	95	100.0	20	6 AAB64805	AAB64805 Interleuk
14	95	100.0	20	6 AAB56570	AAB56570 IL-2 secr
15	95	100.0	20	6 ABR39532	ABR39532 IL-2 sign
16	95	100.0	20	6 AAB33898	AAB33898 Human int
17	95	100.0	20	6 AAB14038	AAB14038 Interleuk
18	95	100.0	20	6 AAB72891	AAB72891 Interleuk
19	95	100.0	20	6 ABO09663	ABO09663 Interleuk
20	95	100.0	20	6 ABA07066	ABA07066 Interleuk
21	95	100.0	20	7 ADA07015	ADA07015 IL-2 secr
22	95	100.0	20	7 ADB66862	ADB66862 Fusion nu
23	95	100.0	20	7 AAB39843	AAB39843 Interleuk
24	95	100.0	20	7 ADD28919	ADD28919 Interleuk

25	95	100.0	20	7 ADE10754	ADE10754 Structura
26	95	100.0	20	7 ADF90387	ADF90387 Secretary
27	95	100.0	20	7 ABO64387	ABO64387 Interleuk
28	95	100.0	20	7 ADI26400	ADI26400 Interleuk
29	95	100.0	20	7 ADJ53830	ADJ53830 Interleuk
30	95	100.0	20	8 ADI36233	ADI36233 Interleuk
31	95	100.0	20	8 ADK15773	ADK15773 Fusion pr
32	95	100.0	20	8 ADM24765	ADM24765 Interleuk
33	95	100.0	20	8 ADL23804	ADL23804 Interleuk
34	95	100.0	20	9 ADK55475	ADK55475 IL-2 secr
35	95	100.0	20	9 ADY21050	ADY21050 Transdomi
36	95	100.0	20	9 ADZ64559	ADZ64559 Human IL-
37	95	100.0	20	9 AEB53570	AEB53570 IL-2 secr
38	95	100.0	23	6 ADA14765	ADA14765 Human int
39	95	100.0	23	6 ABB73285	ABB73285 Renilla r
40	95	100.0	23	6 ADA37434	ADA37434 Human int
41	95	100.0	23	8 ADR43967	ADR43967 Human int
42	95	100.0	23	8 AEB25493	AEB25493 Interleuk
43	95	100.0	26	6 ABU10201	ABU10201 Interleuk
44	95	100.0	49	2 AAB83059	AAB83059 Human IL-
45	95	100.0	64	6 ABB70796	ABB70796 Human ext

ALIGNMENTS

RESULT 1
AAP60901
ID AAP60901 standard; peptide; 20 AA.
XX
XX AAP60901;
AC 25-MAR-2003 (revised)
XX 03-JUL-1991 (first entry)
DT
DT
XX Sequence N-terminal to novel human T-cell growth factor.
DE
XX atCGF; antitumour; cancer; IL-2; immunoregulatory; AIDS; cytomegalovirus;
KM herpes; tuberculosis; leprosis.
XX
XX Homo sapiens.
OS
XX W08505124-A.
XX
XX 21-NOV-1985.
PD
XX
XX 02-MAY-1985; 85WO-EP000194.
XX
XX 08-MAY-1984; 84US-00608228.
PR 07-APR-1986; 86US-00849234.
XX
XX (SANO) SANDOZ AG.
XX (GEMT) GENETICS INST INC.
XX
XX Clark SC;
XX
XX WPI; 1986-028179/04.
XX
XX New human T-cell growth factor from m-RNA of plasma source - useful as
PT immuno-regulatory agent for therapeutic use, as antimycotic and antiviral
PT agent, for assisting antitumour treatments etc.
XX
XX Claim 4; Page 54; 66pp; English.
XX
XX Human T-cell growth factor (atCGF) is distinct from TCGF (IL-2) may be
XX purified and recovered with a higher yield. It is useful in supporting
XX activated mammalian T-cell growth eg. in culture media. It may also be
XX used as an antimycotic, immunoregulatory antiviral and antibacterial
XX agent treating AIDS, SCIDS, congenital immunodeficiency,
XX cytomegalovirus and herpes infections, tuberculosis and leprosis.
XX (Updated on 25-MAR-2003 to correct PA field.)
XX
XX Sequence 20 AA;

GenCore version 5.1.6
Copyright (c) 1993 - 2006 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: January 4, 2006, 15:22:52 : Search time 3720 Seconds

(without alignments)
12544.671 Million cell updates/sec

Title: US-10-688-299-51

Perfect score: 7002
Sequence: 1 tggccatgcatactgtgta.....taccgcatacagattgacctat 7002

Scoring table: IDENTITY_NUC
Gapop 10.0, Gapext 1.0

Searched: 496997 seqs, 3332346308 residues

Total number of hits satisfying chosen parameters: 9993994

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%

Listing first 45 summaries

Database :

N Geneseq 21: *
1: Geneseqm1980s: *
2: Geneseqm1990s: *
3: Geneseqm2000s: *
4: Geneseqm2001as: *
5: Geneseqm2001bs: *
6: Geneseqm2002as: *
7: Geneseqm2002bs: *
8: Geneseqm2003as: *
9: Geneseqm2003bs: *
10: Geneseqm2003cs: *
11: Geneseqm2003ds: *
12: Geneseqm2004as: *
13: Geneseqm2004bs: *
14: Geneseqm2005s: *

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	7002	100.0	7002	14	ADZ64591
2	6029.2	86.1	7802	14	ADZ64590
3	5797.8	82.8	7940	14	ADZ64589
4	3088.8	44.1	10769	14	ADZ64586
5	3085.6	43.6	8152	14	ADW01011
6	2955.2	42.2	7037	6	ABK91461
7	2948.8	42.1	7042	6	ABK91457
8	2935.8	41.9	6965	6	ABK91459
9	2934.8	41.9	6970	6	ABK91454
10	2928.2	41.8	7003	6	ABK91521
11	2918.8	41.7	6902	10	ACCT71562
12	2917.2	41.7	6869	14	ADZ50977
13	2916.6	41.7	6872	6	ABK91542
14	2915.4	41.6	7003	2	AAK59390
15	2913.6	41.6	6859	6	ABK91458
16	2913	41.6	7001	2	AAK89795
17	2910.2	41.6	6861	6	ABK91534
18	2909.2	41.5	6978	6	AAK38657
19	2909.2	41.5	6978	10	ABZ58706

20	2908.6	41.5	7099	4	AAH22814
21	2908.4	41.5	6940	10	ACCT71535
22	2907.2	41.5	6856	6	ABK91462
23	2906.8	41.5	6868	10	ACCT71558
24	2905.8	41.5	6836	6	ABK91540
25	2904.6	41.5	7002	10	ACCT71536
26	2903.6	41.5	6846	6	ABK91537
27	2903.2	41.5	6913	10	ACCT71531
28	2902	41.4	6853	6	ABK91538
29	2901.2	41.4	7023	10	ACCT71541
30	2899	41.4	6829	6	ABK91544
31	2899	41.4	6829	14	ADZ50978
32	2898.8	41.4	6889	10	ACCT71539
33	2898.6	41.4	7005	10	ACCT71551
34	2897	41.4	7036	10	ACCT71537
35	2896.8	41.4	7073	2	AAK59391
36	2896.8	41.4	7073	2	AAK89796
37	2896.2	41.4	6836	14	ADZ50976
38	2893.2	41.3	6914	10	ACCT71529
39	2892.8	41.3	7087	10	ACCT71534
40	2892.2	41.3	6824	6	ABK91560
41	2892.2	41.3	6885	10	ACCT71538
42	2891	41.3	6887	10	ACCT71526
43	2890.2	41.3	6800	6	ABK91541
44	2888.2	41.2	7044	10	ACCT71527
45	2887.8	41.2	5742	14	ADZ64587

ALIGNMENTS

RESULT 1
ID ADZ64591 standard; DNA; 7002 BP.
XX ADZ64591;
AC ADZ64591;
XX 30-JUN-2005 (first entry)
DT
XX
DE Expression construct RO71 DNA.
XX
XX vector; gene transfer; DNA cassette; delivery mechanism; cytostatic;
XX cardiovascular-Gen.; immunosuppressive; virulence; antibacterial;
XX anti-inflammatory; antisense therapy; cancer; autoimmune disease;
XX cardiovascular disease; viral infection; bacterial infection;
XX inflammation; de.
XX
XX Synthetic.
XX
XX WO2005035764-A1.
XX
XX 21-APR-2005.
XX
XX 14-OCT-2004; 2004WO-CA001866.
XX
XX 16-OCT-2003; 2003US-00688299.
XX (UTBR-) UNIV BRITISH COLUMBIA.
XX
XX Finn J. MacLachlan I;
XX
XX WPI, 2005-306367/31.
XX
XX Novel expression vector having cassette having RNA polymerase promoters,
XX nucleic acid encoding secretable RNA polymerase having secretion domain
XX PT and nucleic acid encoding target, useful for expressing target
XX therapeutic compounds.
XX
XX Claim 40; SEQ ID NO 51; 117pp; English.
XX
XX This invention describes a novel expression vector, comprising an
XX expression cassette having two components (a) a Cytomegalovirus-derived
XX promoter and a first RNA polymerase promoter (preferably a T7 RNA
XX CC